You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Pfizer stock fell to the lowest closing price since 2012, putting its yield near 8%, after cautious comments from a UBS ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance ... phone line for doctors and patients to call Pfizer (PFE) directly for help, Jared Hopkins ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

and Nurtec." That figure outpaced the consensus by ~2.9%, according to Seeking Alpha. Also, given the management's cost management initiatives that have been actively implemented, Pfizer's ...

such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT, that should help offset the revenue declines. In addition, Pfizer's pipeline looks promising with 115 programs in ...

Pfizer PFE-1.48%decrease; red down pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.